Guerbet : H1 2026 revenue.

Guerbet reported H1 2026 revenue of €379.2m, down 2.2% YoY (-0.1% at CER and like-for-like), with Q2 revenue down 2.5% (-14.0% in Asia offset by Americas recovery of +4.8%). The company guided 2026 to revenue stable/slightly down, restated EBITDA margin around 8% (including ~€35m Raleigh remediation costs) and free cash flow of -€50m to -€70m due to lower EBITDA, higher CAPEX and restructuring costs. Ahead of the H1 results reset, Guerbet secured a waiver on its net debt/EBITDA covenant for multiple test dates and is discussing refinancing by 31 Oct 2026.

Analysis

The equity story is shifting from a temporary operating disruption to a balance-sheet and capital-structure story. A waiver removes near-term default risk, but it usually comes with a higher cost of capital, tighter lender control, and a longer runway for any equity de-rating to work through; that matters more than the modest sales stabilization. In the next 1-3 months, the stock should trade less on revenue cadence and more on refinancing terms, with any hint of equity dilution or secured debt likely to compress the multiple further.

Operationally, the key second-order effect is that the Raleigh normalization may recover lost share, but only gradually: in regulated imaging consumables, customers often dual-source after a supply shock, so the rebound in the Americas is not automatically a full snapback. The bigger structural headwind is China, where the issue is not cyclical demand but a lower-spend purchasing regime that can force a smaller local commercial footprint and pressure regional margins for several quarters.

Contrarian view: the market may be underestimating how much of the bad news is already in the P&L, while overestimating the durability of the financing overhang. If management can refinance without equity and show batch-release normalization by year-end, the stock can bounce sharply because the earnings base is still recoverable; if not, this becomes a classic lenders-over-equity situation. Falsifier: announced refinancing that extends maturities with no dilution and no punitive covenant reset, plus clear evidence of Americas share recovery into the H2 results date.

Key Decisions for Investors

• Short MEDD/GBT on any post-announcement relief rally, targeting the 4-8 week window into the Sep. 28 results and Oct. 31 refinancing deadline; thesis is capital-structure de-rating, with upside for the short if terms include dilution, security, or a meaningful coupon step-up.
• If liquidity/borrow is available, pair short MEDD/GBT against a broader European healthcare basket or medtech proxy for 1-3 months; this isolates the refinancing risk while reducing sector beta.
• Do not buy the equity until refinancing terms are explicit; an equity raise or covenant reset would likely be the next leg down. Reassess only if net leverage and FCF guidance improve versus current expectations.
• Watch for a Q3 operating inflection in the Americas and no further deterioration in Asia; if Q3 shows continued China weakness and no margin recovery, extend the short into year-end.
• For more risk-tolerant accounts, consider put-spread exposure into the results date rather than outright stock shorting; the setup is binary around financing language, and downside can accelerate if lenders demand security or asset divestitures.